TLSATiziana Life Sciences Ltd

Nasdaq tizianalifesciences.com


$ 0.86 $ 0.00 (0 %)    

Friday, 19-Jul-2024 15:57:38 EDT
QQQ $ 475.02 $ -4.25 (-0.89 %)
DIA $ 402.92 $ -3.77 (-0.93 %)
SPY $ 548.99 $ -3.67 (-0.66 %)
TLT $ 92.97 $ -0.55 (-0.59 %)
GLD $ 221.79 $ -4.05 (-1.79 %)
$ 0.85
$ 0.87
$ 0.00 x 0
$ 0.00 x 0
$ 0.86 - $ 0.87
$ 0.41 - $ 1.05
153,659
na
87.62M
$ 0.77
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

TSLANVDAWAYAITLRYQQQAAPLAVGOSMCIAMZNData from https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment 

 tiziana-life-sciences-reports-six-month-qualitative-results-for-all-10-non-active-secondary-progressive-multiple-sclerosis-patients-enrolled-in-intermediate-size-patient-population-expanded-access-program

Qualitative improvements in PET imaging seen in 80% of non-active Secondary Progressive Multiple Sclerosis (na-SPMS) Expanded A...

 tiziana-life-sciences-reports-3-month-neuroimaging-scores-in-multiple-sclerosis-patients-receiving-intranasal-foralumab-a-primary-endpoint-with-clinical-measures-of-edss-disability-and-mfis-fatigue-is-currently-underway

Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing brea...

 tiziana-life-sciences-announces-fda-allowance-for-additional-patients-to-be-enrolled-in-intranasal-foralumab-multiple-sclerosis-expanded-access-program

Program to expand from 10 patients to a total of 30 patients.

 tiziana-life-sciences-announces-additional-clinical-improvements-among-multiple-sclerosis-patients-in-its-expanded-access-program

Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing brea...